Heart and Vessels

, Volume 25, Issue 4, pp 294–298 | Cite as

Characterization of patients with bleeding complications who are at increased risk of death after percutaneous coronary intervention

  • Gjin Ndrepepa
  • Dritan Keta
  • Stefanie Schulz
  • Julinda Mehilli
  • Anette Birkmeier
  • Franz-Josef Neumann
  • Albert Schömig
  • Adnan Kastrati
Original Article


Bleeding complications in patients undergoing percutaneous coronary interventions (PCIs) are associated with increased risk of subsequent mortality. We undertook this study to characterize the subset of patients with bleeding complications who are at an increased risk of death within the first year after a PCI procedure. The study included 331 patients with bleeding complications among 9 954 patients who underwent PCI. The primary outcome analysis was 1-year mortality. Within the first year following PCI there were 39 deaths among 331 patients (11.8%), with bleeding complications and 240 deaths among 9 623 patients without bleeding complications (Kaplan-Meier estimates of 1-year mortality; 11.8% vs 2.5%, odds ratio 5.09, 95% confidence interval 3.76–6.90, P < 0.001). Time to death (median [25th–75th percentiles]) was 38.5 [7.2–125.9] days in patients with bleeding complications vs 137.1 [68.3–234.0] days in patients without bleeding complications (P < 0.001). Compared with survivors (n = 292), nonsurvivors (n = 39) had a significantly more adverse risk profile. The Cox proportional hazards model identified the elevated troponin level as the only independent correlate of 1-year mortality (hazard ratio = 2.35, 95% confidence interval 1.04–5.31, P = 0.039). In conclusion, patients with peri-PCI bleeding complications who die have a more adverse cardiovascular risk profile than patients with bleeding complications who survive the first year after PCI. Patients with bleeding complications and an elevated troponin level are at high risk of death within the first year following PCI. The majority of deaths in patients with peri-PCI bleeding occur within the first 3 months after PCI procedure.

Key words

Bleeding Mortality Percutaneous coronary intervention Troponin 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Kirtane AJ, Piazza G, Murphy SA, Budiu D, Morrow DA, Cohen DJ, Peterson E, Lakkis N, Herrmann HC, Palabrica TM, Gibson CM; TIMI Study Group (2006) Correlates of bleeding events among moderate- to high-risk patients undergoing percutaneous coronary intervention and treated with eptifibatide: observations from the PROTECT-TIMI-30 trial. J Am Coll Cardiol 47:2374–2379PubMedCrossRefGoogle Scholar
  2. 2.
    Kinnaird TD, Stabile E, Mintz GS, Lee CW, Canos DA, Gevorkian N, Pinnow EE, Kent KM, Pichard AD, Satler LF, Weissman NJ, Lindsay J, Fuchs S (2003) Incidence, predictors, and prognostic implications of bleeding and blood transfusion following percutaneous coronary interventions. Am J Cardiol 92:930–935PubMedCrossRefGoogle Scholar
  3. 3.
    Moscucci M, Fox KA, Cannon CP, Klein W, López-Sendón J, Montalescot G, White K, Goldberg RJ (2003) Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 24:1815–1823PubMedCrossRefGoogle Scholar
  4. 4.
    Rao SV, O’Grady K, Pieper KS, Granger CB, Newby LK, Van de Werf F, Mahaffey KW, Califf RM, Harrington RA (2005) Impact of bleeding severity on clinical outcomes among patients with acute coronary syndromes. Am J Cardiol 96:1200–1206PubMedCrossRefGoogle Scholar
  5. 5.
    Segev A, Strauss BH, Tan M, Constance C, Langer A, Goodman SG; Canadian Acute Coronary Syndromes Registries Investigators (2005) Predictors and 1-year outcome of major bleeding in patients with non-ST-elevation acute coronary syndromes: insights from the Canadian Acute Coronary Syndrome Registries. Am Heart J 150: 690–694PubMedCrossRefGoogle Scholar
  6. 6.
    Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S (2006) Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 114:774–782PubMedCrossRefGoogle Scholar
  7. 7.
    Manoukian SV, Feit F, Mehran R, Voeltz MD, Ebrahimi R, Hamon M, Dangas GD, Lincoff AM, White HD, Moses JW, King SB 3rd, Ohman EM, Stone GW (2007) Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 49:1362–1368PubMedCrossRefGoogle Scholar
  8. 8.
    Ndrepepa G, Berger PB, Mehilli J, Seyfarth M, Neumann FJ, Schömig A, Kastrati A (2008) Periprocedural bleeding and 1-year outcome after percutaneous coronary interventions: appropriateness of including bleeding as a component of a quadruple end point. J Am Coll Cardiol 51:690–697PubMedCrossRefGoogle Scholar
  9. 9.
    Kastrati A, Mehilli J, Schulhen H, Dirschinger J, Dotzer FJ, Bollwein H, Volmer C, Gawaz M, Berger PB, Schomig A, for the Intracoronary Stenting and Antithrombotic Regimen-Rapid Early Action for Coronary Treatment (ISAR-REACT) Study Investigators (2004) A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 350:232–238PubMedCrossRefGoogle Scholar
  10. 10.
    Mehilli J, Kastrati A, Schühlen H, Dibra A, Dotzer F, von Beckerath N, Bollwein H, Pache J, Dirschinger J, Berger PB, Schömig A; for the Intracoronary Stenting and Antithrombotic Regimen: Is abciximab a superior way to eliminate elevated thrombotic risk in diabetics (ISAR-SWEET) Study Investigators (2004) Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 110:3627–3635PubMedCrossRefGoogle Scholar
  11. 11.
    Hausleiter J, Kastrati A, Mehilli J, Schuhlen H, Pache J, Dotzer F, Glatthor C, Siebert S, Dirschinger J, Schomig A, for the ISARSMART-2 Investigators (2004) A randomized trial comparing phosphorylcholine-coated stenting with balloon angioplasty as well as abciximab with placebo for restenosis reduction in small coronary arteries. J Intern Med 256:388–397PubMedCrossRefGoogle Scholar
  12. 12.
    Kastrati A, Mehilli J, Neumann FJ, Dotzer F, Berg J, Bollwein H, Graf I, Ibrahim M, Pache J, Seyfarth M, Schuhlen H, Dirschinger J, Berger PB, Schomig A, for the Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment (ISAR-REACT 2) Trial Investigators (2006) A randomized, double-blind, placebo-controlled trial of glycoprotein IIb/IIIa inhibition with abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment. JAMA 295:1531–1538PubMedCrossRefGoogle Scholar
  13. 13.
    Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A; ISAR-REACT 3 Trial Investigators (2008) Bivalirudin versus unfractionated heparin during percutaneous coronary intervention. N Engl J Med 359:688–696PubMedCrossRefGoogle Scholar
  14. 14.
    TIMI Study Group. Definitions used in TIMI trials. Available at: http://www.timi.org. Accessed March 10th, 2009
  15. 15.
    Kasai T, Miyauchi K, Kajimoto K, Kubota N, Kurata T, Daida H (2008) Influence of diabetes on >10-year outcomes after percutaneous coronary intervention. Heart Vessels 23:149–154PubMedCrossRefGoogle Scholar
  16. 16.
    Kubota N, Kasai T, Miyauchi K, Njaman W, Kajimoto K, Akimoto Y, Kojima T, Ken Y, Takeshi K, Hiroyuki D (2008) Therapy with statins and aspirin enhances long-term outcome of percutaneous coronary intervention. Heart Vessels 23:35–39PubMedCrossRefGoogle Scholar
  17. 17.
    Spencer FA, Moscucci M, Granger CB, Gore JM, Goldberg RJ, Steg PG, Goodman SG, Budaj A, FitzGerald G, Fox KA; GRACE Investigators (2007) Does comorbidity account for the excess mortality in patients with major bleeding in acute myocardial infarction? Circulation 116:2793–2801PubMedCrossRefGoogle Scholar
  18. 18.
    Rao SV, Jollis JG, Harrington RA, Granger CB, Newby LK, Armstrong PW, Moliterno DJ, Lindblad L, Pieper K, Topol EJ, Stamler JS, Califf RM (2004) Relationship of blood transfusion and clinical outcomes in patients with acute coronary syndromes. JAMA 292:1555–1562PubMedCrossRefGoogle Scholar
  19. 19.
    Welch HG, Meehan KR, Goodnough LT (1992) Prudent strategies for elective red blood cell transfusion. Ann Intern Med 116: 393–402PubMedGoogle Scholar
  20. 20.
    McMahon TJ, Moon RE, Luschinger BP, Carraway MS, Stone AE, Stolp BW, Gow AJ, Pawloski JR, Watke P, Singel DJ, Piantadosi CA, Stamler JS (2002) Nitric oxide in the human respiratory cycle. Nat Med 8:711–717PubMedGoogle Scholar
  21. 21.
    Fransen E, Maessen J, Dentener M, Senden N, Buurman W (1999) Impact of blood transfusions on inflammatory mediator release in patients undergoing cardiac surgery. Chest 116:1233–1239PubMedCrossRefGoogle Scholar
  22. 22.
    Perrotta PL, Snyder EL (2001) Non-infectious complications of transfusion therapy. Blood Rev 15:69–83PubMedCrossRefGoogle Scholar
  23. 23.
    Wang TY, Xiao L, Alexander KP, Rao SV, Kosiborod MN, Rumsfeld JS, Spertus JA, Peterson ED (2008) Antiplatelet therapy use after discharge among acute myocardial infarction patients with in-hospital bleeding. Circulation 118:2139–2145PubMedCrossRefGoogle Scholar
  24. 24.
    Stone GW, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Dangas G, Wong SC, Kirtane AJ, Parise H, Mehran R; HORIZONS-AMI Trial Investigators (2008) Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358:2218–2230PubMedCrossRefGoogle Scholar
  25. 25.
    Stone GW, Ware JH, Bertrand ME, Lincoff AM, Moses JW, Ohman EM, White HD, Feit F, Colombo A, McLaurin BT, Cox DA, Manoukian SV, Fahy M, Clayton TC, Mehran R, Pocock SJ; ACUITY Investigators (2007) Antithrombotic strategies in patients with acute coronary syndromes undergoing early invasive management: one-year results from the ACUITY trial. JAMA 298:2497–2506PubMedCrossRefGoogle Scholar
  26. 26.
    Iijima R, Ndrepepa G, Mehilli J, Byrne RA, Schulz S, Neumann FJ, Richardt G, Berger PB, Schömig A, Kastrati A (2009) Profile of bleeding and ischaemic complications with bivalirudin and unfractionated heparin after percutaneous coronary intervention. Eur Heart J 30:290–296PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2010

Authors and Affiliations

  • Gjin Ndrepepa
    • 1
  • Dritan Keta
    • 1
  • Stefanie Schulz
    • 1
  • Julinda Mehilli
    • 1
  • Anette Birkmeier
    • 1
  • Franz-Josef Neumann
    • 2
  • Albert Schömig
    • 1
    • 3
  • Adnan Kastrati
    • 1
  1. 1.Deutsches HerzzentrumTechnische UniversitätMunichGermany
  2. 2.Herz-ZentrumBad KrozingenGermany
  3. 3.1. Medizinische Klinik rechts der IsarTechnische UniversitätMunichGermany

Personalised recommendations